Adams Respiratory Therapeutics reports approval from FDA for grape-flavoured Delsym

Tue. October 02, 2007; Posted: 05:09 AM

7 Stocks You Need To Know For Tomorrow -- Free Newsletter

Oct 02, 2007 (M2 EQUITYBITES via COMTEX) -- ARXT | charts | news | PowerRating -- Adams Respiratory Therapeutics Inc (Nasdaq: aARxT), a specialty pharmaceutical company, reported on 1 October that the company has received approval from the Food and Drug Administration (FDA) for its supplemental New Drug Application for a grape-flavoured formulation of Delsym Extended-Release Suspension for 12-hour non-prescription liquid cough suppressant.

The company said it will begin distribution of grape Delsym product to its trade customers with immediate effect.

Delsym is an over-the-counter (OTC) liquid that reportedly controls cough for a full 12 hours with a single dose, providing all day or all night cough suppression with each dose. The patented single-ingredient formula is currently available for both children and adults.

Comments on this story may be sent to admin@m2.com

For full details for ARXT click here.

Morning Coffee with TradingMarkets -- Free Newsletter

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.